Melanoma of the Upper Limb and Shoulder: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019.

SEER dermato-oncology epidemiology malignant melanoma survival analysis upper limb and shoulder

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 Nov 2022
Historique:
received: 30 09 2022
revised: 07 11 2022
accepted: 15 11 2022
entrez: 26 11 2022
pubmed: 27 11 2022
medline: 27 11 2022
Statut: epublish

Résumé

(1) Background: Melanoma is the most common life-threatening cancer among skin cancers. Almost all locations of the skin can be affected by melanoma, and the upper limbs are one of the most frequent locations. We aimed to study the epidemiology and survival outcomes of patients with melanoma localized in the upper extremities compared with other sites. (2) Methods: The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database is considered the most representative of the U.S. population; we extracted melanoma cases diagnosed between 2000 and 2019. Several characteristics, including demographical, pathological, and therapeutic, were recorded, and upper extremity melanomas and melanomas from other areas were compared. Overall survival was assessed, and the groups were compared. (3) Results: 69,436 patients had melanoma in the upper limbs and shoulders and 204,794 in other body parts. Overall, 35,267 patients with upper extremity melanoma were males, 34,169 were females, and the mean age was 60. For the rest of the body, there were 118,654 males and 86,140 females, with a mean age of 59. Surgery alone was the most commonly used treatment, while radiation therapy was the least used for all sites. Women appear to have better survival than men. Superficial spreading melanoma is the least lethal subtype, while nodular melanoma is the most dangerous. (4) Conclusion: Women under 50 are more at risk than men of the same age. The trend reverses after age 50 where men are at greater risk. In addition to gender and age, disease stage and major histologic subtypes influence survival.

Identifiants

pubmed: 36428763
pii: cancers14225672
doi: 10.3390/cancers14225672
pmc: PMC9688102
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cochrane Database Syst Rev. 2019 Jun 03;6:CD012352
pubmed: 31157404
Am J Epidemiol. 2016 May 1;183(9):824-33
pubmed: 27045074
JAMA Dermatol. 2019 Jan 1;155(1):39-49
pubmed: 30477003
Int J Epidemiol. 2000 Jun;29(3):416-23
pubmed: 10869312
Br J Dermatol. 2011 Oct;165(4):859-64
pubmed: 21623751
Ann Plast Surg. 2015 Jan;74(1):30-3
pubmed: 23759966
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
Otolaryngol Head Neck Surg. 2022 Aug;167(2):286-297
pubmed: 34699278
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1241-4
pubmed: 15894679
Arch Dermatol. 2012 Jan;148(1):30-6
pubmed: 21931016
Ital J Dermatol Venerol. 2021 Jun;156(3):300-321
pubmed: 33982546
JAMA Dermatol. 2022 May 1;158(5):495-503
pubmed: 35353115
J Am Acad Dermatol. 2014 Oct;71(4):611.e1-611.e10; quiz 621-2
pubmed: 25219717
Cancer Biol Ther. 2019;20(11):1366-1379
pubmed: 31366280
Eur J Cancer. 2022 Jul;170:256-284
pubmed: 35623961
Hand Clin. 2014 May;30(2):153-63. v
pubmed: 24731607
J Am Acad Dermatol. 2019 Jan;80(1):1-12
pubmed: 30553298
Am J Dermatopathol. 2022 Nov 1;44(11):799-805
pubmed: 35925149
Dermatol Surg. 2004 Nov;30(11):1371-5; discussion 1375-6
pubmed: 15522016
Cancer Causes Control. 1999 Oct;10(5):407-16
pubmed: 10530611
Ann Surg Oncol. 2014 Nov;21(12):3985-91
pubmed: 24912613
Proc (Bayl Univ Med Cent). 2020 Jul 7;33(4):557-559
pubmed: 33100528
MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):591-6
pubmed: 26042651
Cancer. 2005 Feb 1;103(3):616-24
pubmed: 15630700
J Am Coll Health. 2020 Feb-Mar;68(2):163-168
pubmed: 30485157
J Am Acad Dermatol. 2007 May;56(5):768-73
pubmed: 17337091
Hematol Oncol Clin North Am. 2019 Feb;33(1):25-38
pubmed: 30497675
J Clin Oncol. 2006 Jul 1;24(19):3172-7
pubmed: 16809740
Sci Rep. 2021 Oct 25;11(1):21012
pubmed: 34697327
Int J Cancer. 2014 Jun 1;134(11):2735-41
pubmed: 24288300
Acta Derm Venereol. 2020 Jun 3;100(11):adv00136
pubmed: 32346751
Acta Derm Venereol. 2021 Apr 12;101(4):adv00427
pubmed: 33686445
Clin Transl Oncol. 2019 Apr;21(4):412-419
pubmed: 30182208
J Am Acad Dermatol. 2006 May;54(5):783-92
pubmed: 16635658
JAMA Dermatol. 2020 May 1;156(5):553-560
pubmed: 32211827

Auteurs

Solange N Walz (SN)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.

Jérôme Martineau (J)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.

Matteo Scampa (M)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.

Daniel F Kalbermatten (DF)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.

Carlo M Oranges (CM)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.

Classifications MeSH